South Korean conglomerate SK Holdings jumped decidedly into contract manufacturing a couple of years ago with deals for API plants in Ireland and the U.S. Now, it is rolling those into a group that includes its plant in South Korea in hopes of becoming a key player in the business.
The drugmaker over the weekend said it is merging its SK biotek in Korea and SK biotek in Ireland along with Ampac Fine Chemicals in the U.S. to form SK Pharmteco, the Korea Biomedical Review reports. It has named Aslam Malik, CEO of Ampac, to head the CDMO and established its headquarters in Sacramento, California.
SK Pharmteco believes the integration will help it attract customers and sharpen its competitive edge, the report said.
SK, which had been an ingredient supplier to Bristol-Myers Squibb, last year snapped up a BMS plant in Swords, Ireland, with 300 employees for an undisclosed sum. Under the deal, SK agreed to continue to produce the products BMS made at the plant, which included the API for BMS and Pfizer’s anticoagulant Eliquis.
A month later, it closed a deal to buy Ampac, a U.S. contract manufacturer that makes APIs for controlled substances, among other things. That gave SK a network of U.S. facilities in Rancho Cordova and El Dorado Hills in California; La Porte, Texas; and Petersburg, Virginia.
By Eric Palmer
Source: Fierce Pharma
Novartis will acquire Mariana’s lead candidate MC-339, a radioligand therapy (RLT) designed to target small-cell lung cancer. Last year, Mariana had raised $175m in a Series B round from several funds and pharma giant Eli Lilly.
The company’s aspiration to expand the use of its obesity products to cardiovascular indications has been successful. In March, its blockbuster drug Wegovy was approved by the US Food and Drug Administration (FDA) for reducing the risk of cardiovascular diseases in obese or overweight adults.
Massachusetts-based Deciphera brings to the table an extensive kinase inhibitor pipeline, kinase drug discovery expertise, and a strong commercial and sales platform in the US and European markets that is meant to advance Ono’s capabilities and presence in the oncology space.